Your browser doesn't support javascript.
loading
Immune homeostasis and regulation of the interferon pathway require myeloid-derived Regnase-3.
von Gamm, Matthias; Schaub, Annalisa; Jones, Alisha N; Wolf, Christine; Behrens, Gesine; Lichti, Johannes; Essig, Katharina; Macht, Anna; Pircher, Joachim; Ehrlich, Andreas; Davari, Kathrin; Chauhan, Dhruv; Busch, Benjamin; Wurst, Wolfgang; Feederle, Regina; Feuchtinger, Annette; Tschöp, Matthias H; Friedel, Caroline C; Hauck, Stefanie M; Sattler, Michael; Geerlof, Arie; Hornung, Veit; Heissmeyer, Vigo; Schulz, Christian; Heikenwalder, Mathias; Glasmacher, Elke.
Afiliação
  • von Gamm M; Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Schaub A; Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Jones AN; Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Wolf C; Institute of Structural Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Behrens G; Center for Integrated Protein Science Munich, Chemistry Department, Technical University of Munich, Garching, Germany.
  • Lichti J; Institute of Environmental Medicine, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Essig K; Institute for Immunology, Biomedical Center, Ludwig-Maximilians-Universität München, Planegg-Martinsried, Germany.
  • Macht A; Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Pircher J; Roche Pharma Research and Early Development, Large Molecule Research, Roche Innovation Center Munich, Penzberg, Germany.
  • Ehrlich A; Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Davari K; Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany.
  • Chauhan D; Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Ludwig-Maximilians-University, Munich, Germany.
  • Busch B; Medigene Immunotherapies, Planegg-Martinsried, Germany.
  • Wurst W; Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Feederle R; Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Feuchtinger A; Institute of Developmental Genetics, Helmholtz Zentrum München, Munich, Germany.
  • Tschöp MH; Technische Universität München-Weihenstephan, Neuherberg-Munich, Germany.
  • Friedel CC; German Center for Neurodegenerative Diseases, Munich, Germany.
  • Hauck SM; Munich Cluster for Systems Neurology, Munich, Germany.
  • Sattler M; Monoclonal Antibody Core Facility, Institute for Diabetes and Obesity, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Geerlof A; Research Unit Analytical Pathology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Hornung V; Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Heissmeyer V; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany.
  • Schulz C; Institute for Informatics, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Heikenwalder M; Research Unit Protein Science, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
  • Glasmacher E; Institute of Structural Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
J Exp Med ; 216(7): 1700-1723, 2019 07 01.
Article em En | MEDLINE | ID: mdl-31126966
ABSTRACT
The RNase Regnase-1 is a master RNA regulator in macrophages and T cells that degrades cellular and viral RNA upon NF-κB signaling. The roles of its family members, however, remain largely unknown. Here, we analyzed Regnase-3-deficient mice, which develop hypertrophic lymph nodes. We used various mice with immune cell-specific deletions of Regnase-3 to demonstrate that Regnase-3 acts specifically within myeloid cells. Regnase-3 deficiency systemically increased IFN signaling, which increased the proportion of immature B and innate immune cells, and suppressed follicle and germinal center formation. Expression analysis revealed that Regnase-3 and Regnase-1 share protein degradation pathways. Unlike Regnase-1, Regnase-3 expression is high specifically in macrophages and is transcriptionally controlled by IFN signaling. Although direct targets in macrophages remain unknown, Regnase-3 can bind, degrade, and regulate mRNAs, such as Zc3h12a (Regnase-1), in vitro. These data indicate that Regnase-3, like Regnase-1, is an RNase essential for immune homeostasis but has diverged as key regulator in the IFN pathway in macrophages.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ribonucleases / Interferons / Células Mieloides / Homeostase / Imunidade Inata Limite: Animals Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ribonucleases / Interferons / Células Mieloides / Homeostase / Imunidade Inata Limite: Animals Idioma: En Ano de publicação: 2019 Tipo de documento: Article